Oral Contraceptive / Nevirapine Interaction Trial, New York and San Francisco
A six-week pharmacokinetic trial to see if the oral contraceptive Ortho Novum affects levels of the antiretroviral nevirapine, or vice versa, is now recruiting women in New York and San Francisco.Participants must have an undetectable viral load, CD4 count over 100, have no active infection, and be on a stable antiretroviral regimen (which cannot include current use of ritonavir or delavirdine, although previous use may be OK). There are additional entry criteria.
At the San Francisco site, participants will be compensated $500 on completion of the study; free parking will be provided, and transportation and child care costs can be reimbursed. At the New York site, volunteers will be compensated similarly. Some time in the clinic will be required for blood tests.
This may be the first trial for drug interactions between antiretrovirals and oral contraceptives.
For more information, in San Francisco call Sal Iacopelli, 415-353-6215. In New York, call Carsandra Diggs or Steve Nowling at the Clinical Trials Unit at Beth Israel Medical Center, 212-420-4519.
